Liminal BioSciences Reports Second Quarter Financial Results 2023

LAVAL, QC and CAMBRIDGE, England, Aug. 8, 2023 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), a development-stage biopharmaceutical company focused on discovering and developing distinctive novel small molecule therapeutics for metabolic, inflammatory, and fibrotic diseases, today reported its financial results for the second quarter ended June 30, 2023. 

Read more at prnewswire.com